Covered recipient · General Payments record
MINESH RAJPAL
Allopathic & Osteopathic Physicians Internal Medicine Nephrology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2023 · Entire year
$97,185.09
158 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2023 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $53,384.50 | 27 |
| Consulting Fee | $15,053.00 | 9 |
| Travel and Lodging | $13,535.76 | 31 |
| Honoraria | $11,400.00 | 4 |
| Food and Beverage | $3,788.69 | 86 |
| Education | $23.14 | 1 |
By paying entity
PY2023 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | $34,499.67 | 48 |
| Amgen Inc. | $15,674.10 | 22 |
| Horizon Therapeutics plc | $13,601.72 | 19 |
| Travere Therapeutics, Inc. | $12,973.94 | 29 |
| GlaxoSmithKline, LLC. | $10,263.76 | 9 |
| Calliditas Therapeutics US Inc. | $4,496.26 | 3 |
| Bayer Healthcare Pharmaceuticals Inc. | $4,139.87 | 10 |
| AstraZeneca UK Limited | $1,167.00 | 1 |
| Otsuka America Pharmaceutical, Inc. | $79.78 | 4 |
| Alexion Pharmaceuticals, Inc. | $56.40 | 2 |
| Takeda Pharmaceuticals U.S.A., Inc. | $38.80 | 2 |
| Daiichi Sankyo Inc. | $37.12 | 2 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $28.88 | 1 |
| Novartis Pharmaceuticals Corporation | $27.91 | 1 |
| AKEBIA THERAPEUTICS INC | $27.49 | 1 |
| OPKO Pharmaceuticals, LLC | $23.14 | 1 |
| Veloxis Pharmaceuticals, Inc. | $17.97 | 1 |
| GENZYME CORPORATION | $17.09 | 1 |
| Ultragenyx Pharmaceutical Inc. | $14.19 | 1 |
Page 3 of 4; records 101–150 of 158 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
MINESH RAJPAL
NPI 1568760502 · CMS profile ID 1494173
Allopathic & Osteopathic Physicians / Internal Medicine / Nephrology
PEORIA, AZ
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 4; records 101–150 of 158 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1568760502?year=2023&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- MINESH RAJPAL, NPI 1568760502, CMS profile ID 1494173. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 158 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1568760502?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- APA 7
- IndustryPayments. (2026). MINESH RAJPAL, NPI 1568760502, CMS profile ID 1494173. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 158 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1568760502?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- Bluebook
- MINESH RAJPAL, NPI 1568760502, CMS profile ID 1494173, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 158 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1568760502?year=2023&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30
158 matching records · $97,185.09 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–150 of 158.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $27.91 | 05/25/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 992747569 | CMS |
| GENZYME CORPORATION | $17.09 | 05/24/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1049897579 | CMS |
| AstraZeneca Pharmaceuticals LP | $650.00 | 05/23/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1014301489 | CMS |
| AstraZeneca Pharmaceuticals LP | $1,700.00 | 05/17/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1014483577 | CMS |
| Travere Therapeutics, Inc. | $6.28 | 05/17/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1059553791 | CMS |
| Horizon Therapeutics plc | $16.11 | 05/15/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 987062869 | CMS |
| Amgen Inc. | $1,470.00 | 05/11/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1020643113 | CMS |
| AstraZeneca Pharmaceuticals LP | $18.65 | 05/11/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1011259291 | CMS |
| Amgen Inc. | $2,700.00 | 05/10/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1020643101 | CMS |
| Amgen Inc. | $450.00 | 05/10/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1020643105 | CMS |
| AstraZeneca Pharmaceuticals LP | $337.00 | 05/10/2023 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1014204475 | CMS |
| Amgen Inc. | $99.66 | 05/04/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1020643095 | CMS |
| Daiichi Sankyo Inc. | $15.23 | 05/04/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1006431397 | CMS |
| Amgen Inc. | $2,250.00 | 05/02/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1020643099 | CMS |
| GlaxoSmithKline, LLC. | $5,850.00 | 05/02/2023 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1001094912 | CMS |
| AstraZeneca Pharmaceuticals LP | $2,000.00 | 05/01/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015801796 | CMS |
| AstraZeneca Pharmaceuticals LP | $162.28 | 04/25/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1014347663 | CMS |
| AstraZeneca Pharmaceuticals LP | $124.99 | 04/25/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015868529 | CMS |
| Amgen Inc. | $18.96 | 04/24/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1020643107 | CMS |
| Amgen Inc. | $188.26 | 04/24/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1020643109 | CMS |
| Amgen Inc. | $2.95 | 04/20/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1020643091 | CMS |
| Amgen Inc. | $7.74 | 04/20/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1020643093 | CMS |
| AstraZeneca Pharmaceuticals LP | $1,700.00 | 04/19/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015985711 | CMS |
| Amgen Inc. | $2,700.00 | 04/18/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1020643097 | CMS |
| Amgen Inc. | $900.00 | 04/18/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1020643103 | CMS |
| AstraZeneca Pharmaceuticals LP | $100.00 | 04/18/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015945601 | CMS |
| AstraZeneca Pharmaceuticals LP | $40.61 | 04/13/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1011538159 | CMS |
| AstraZeneca Pharmaceuticals LP | $17.50 | 04/13/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1014994119 | CMS |
| Amgen Inc. | $112.36 | 04/11/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1020643115 | CMS |
| Amgen Inc. | $197.95 | 04/11/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1020643117 | CMS |
| AKEBIA THERAPEUTICS INC | $27.49 | 04/04/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1000062671 | CMS |
| Otsuka America Pharmaceutical, Inc. | $19.21 | 03/30/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1014723275 | CMS |
| Travere Therapeutics, Inc. | $24.99 | 03/24/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1059553805 | CMS |
| Travere Therapeutics, Inc. | $24.99 | 03/24/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1059553807 | CMS |
| Travere Therapeutics, Inc. | $59.98 | 03/24/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1059553811 | CMS |
| Travere Therapeutics, Inc. | $74.95 | 03/24/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1059553813 | CMS |
| Travere Therapeutics, Inc. | $292.67 | 03/24/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1059553831 | CMS |
| GlaxoSmithKline, LLC. | $118.34 | 03/23/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1001094519 | CMS |
| Amgen Inc. | $197.95 | 03/21/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1020643111 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $3,122.00 | 03/14/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1000666139 | CMS |
| Horizon Therapeutics plc | $1,600.00 | 03/07/2023 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 987062867 | CMS |
| Ultragenyx Pharmaceutical Inc. | $14.19 | 03/07/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1059055485 | CMS |
| Travere Therapeutics, Inc. | $8.66 | 03/03/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1059553797 | CMS |
| AstraZeneca Pharmaceuticals LP | $31.52 | 02/21/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015661099 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $8.68 | 02/14/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1000550739 | CMS |
| AstraZeneca Pharmaceuticals LP | $22.19 | 02/13/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015781317 | CMS |
| Daiichi Sankyo Inc. | $21.89 | 02/03/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1006388895 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $17.55 | 02/01/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1055553841 | CMS |
| GlaxoSmithKline, LLC. | $11.97 | 01/30/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1001094475 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $813.15 | 01/27/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1000661697 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $2,115,863.03 | 47 |
| PY2024 | Principal investigator | $905,172.25 | 34 |
| PY2023 | Principal investigator | $169,987.90 | 4 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
47 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,967.04 | 12/18/2025 | Non-covered Recipient Entity Panoramic Science Llc | A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3 study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney disease a | No dispute reported | 06/30/2026 | 1225415050 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11,925.00 | 12/17/2025 | Non-covered Recipient Entity Panoramic Health | A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease | No dispute reported | 06/30/2026 | 1220734145 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,217.04 | 12/01/2025 | Non-covered Recipient Entity Panoramic Science Llc | A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3 study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney disease a | No dispute reported | 06/30/2026 | 1225415028 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $40,061.76 | 11/30/2025 | Non-covered Recipient Entity Panoramic Health | A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease | No dispute reported | 06/30/2026 | 1220997380 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39,050.00 | 11/17/2025 | Non-covered Recipient Entity Panoramic Health | A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease | No dispute reported | 06/30/2026 | 1220734143 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,134.04 | 11/11/2025 | Non-covered Recipient Entity Panoramic Science Llc | A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3 study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney disease a | No dispute reported | 06/30/2026 | 1225415366 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $40,061.76 | 10/31/2025 | Non-covered Recipient Entity Panoramic Health | A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease | No dispute reported | 06/30/2026 | 1220997378 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,291.04 | 10/23/2025 | Non-covered Recipient Entity Panoramic Science Llc | A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3 study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney disease a | No dispute reported | 06/30/2026 | 1225414134 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $25,580.00 | 10/22/2025 | Non-covered Recipient Entity Panoramic Health | A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease | No dispute reported | 06/30/2026 | 1220734141 |
| Principal investigator 1 | VERTEX PHARMACEUTICALS INCORPORATED | $35,643.54 | 10/22/2025 | Non-covered Recipient Entity SOUTHWEST KIDNEY INSTITUTE SURPRISE | A Phase 2b/3 Adaptive, Randomized, Active-controlled Study Evaluating the Efficacy, Safety, and Tolerability of Povetacicept Versus Calcineurin Inhibitor in the Treatment of Primary Membranous Nephropathy | No dispute reported | 06/30/2026 | 1214124954 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $40,061.76 | 09/30/2025 | Non-covered Recipient Entity Panoramic Health | A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease | No dispute reported | 06/30/2026 | 1220997376 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,125.00 | 09/24/2025 | Non-covered Recipient Entity Clinical Renal Associates, Ltd | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215519951 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $150.00 | 09/24/2025 | Non-covered Recipient Entity Clinical Renal Associates, Ltd | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215519956 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,010.00 | 09/24/2025 | Non-covered Recipient Entity Clinical Renal Associates, Ltd | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215519960 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $14,693.00 | 09/18/2025 | Non-covered Recipient Entity Panoramic Science Llc | A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3 study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney disease a | No dispute reported | 06/30/2026 | 1225414604 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $18,890.00 | 09/08/2025 | Non-covered Recipient Entity Panoramic Health | A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease | No dispute reported | 06/30/2026 | 1220734139 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $500.00 | 09/04/2025 | Non-covered Recipient Entity Panoramic Science Llc | A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3 study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney disease a | No dispute reported | 06/30/2026 | 1225414602 |
| Principal investigator 1 | Eli Lilly and Company | $168.00 | 09/04/2025 | Non-covered Recipient Entity SOUTHWEST KIDNEY INSTITUTE | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | No dispute reported | 06/30/2026 | 1187890916 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $21,705.00 | 08/18/2025 | Non-covered Recipient Entity Panoramic Health | A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease | No dispute reported | 06/30/2026 | 1220734137 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $40,061.76 | 07/31/2025 | Non-covered Recipient Entity Panoramic Health | A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease | No dispute reported | 06/30/2026 | 1220997374 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $226,149.11 | 07/23/2025 | Non-covered Recipient Entity PANORAMIC HEALTH | a phase III,randomised,double blind,placebo controlled,event driven study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on renal outcomes and cardiovascular mortality in participants with chronic kidney disease and high blood pressure | No dispute reported | 06/30/2026 | 1185545439 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $25,355.00 | 07/07/2025 | Non-covered Recipient Entity Panoramic Health | A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease | No dispute reported | 06/30/2026 | 1220734135 |
| Principal investigator 1 | Amgen Inc. | $35,270.00 | 06/26/2025 | Non-covered Recipient Entity PANORAMIC SCIENCE LLC | A Randomized, Double-blind, Placebo-controlled Phase 4 Clinical Trial to Evaluate the Long-term Safety and Efficacy of Avacopan in Participants With Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis | No dispute reported | 06/30/2026 | 1246646331 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,732.00 | 06/19/2025 | Non-covered Recipient Entity Panoramic Science Llc | A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3 study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney disease a | No dispute reported | 06/30/2026 | 1225412434 |
| Principal investigator 1 | Amgen Inc. | $1,696.00 | 06/13/2025 | Non-covered Recipient Entity SOUTHWEST KIDNEY INSTITUTE, PLC | A Randomized, Double-blind, Placebo-controlled Phase 4 Clinical Trial to Evaluate the Long-term Safety and Efficacy of Avacopan in Participants With Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis | No dispute reported | 06/30/2026 | 1246648506 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $13,080.00 | 06/09/2025 | Non-covered Recipient Entity Panoramic Health | A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease | No dispute reported | 06/30/2026 | 1220734131 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,177.00 | 06/05/2025 | Non-covered Recipient Entity Panoramic Science Llc | A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3 study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney disease a | No dispute reported | 06/30/2026 | 1225412006 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $400.00 | 05/29/2025 | Non-covered Recipient Entity Panoramic Science Llc | A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3 study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney disease a | No dispute reported | 06/30/2026 | 1225412660 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,511.00 | 05/21/2025 | Non-covered Recipient Entity Panoramic Science Llc | BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in partic | No dispute reported | 06/30/2026 | 1225409146 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $16,350.00 | 05/12/2025 | Non-covered Recipient Entity Panoramic Health | A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease | No dispute reported | 06/30/2026 | 1220734133 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $15,927.00 | 04/28/2025 | Non-covered Recipient Entity Panoramic Science Llc | BAY 948862, A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney | No dispute reported | 06/30/2026 | 1225402623 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $9,810.00 | 04/09/2025 | Non-covered Recipient Entity Panoramic Health | A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease | No dispute reported | 06/30/2026 | 1220734129 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $166.00 | 03/12/2025 | Non-covered Recipient Entity Panoramic Science Llc | BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with chronic kidney disease and type 2 diabetes | No dispute reported | 06/30/2026 | 1225402645 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $80,123.52 | 02/28/2025 | Non-covered Recipient Entity Panoramic Health | A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease | No dispute reported | 06/30/2026 | 1220997372 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $3,684.00 | 02/21/2025 | Non-covered Recipient Entity Panoramic Science Llc | BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with chronic kidney disease and type 2 diabetes | No dispute reported | 06/30/2026 | 1225405970 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,228.00 | 02/19/2025 | Non-covered Recipient Entity Panoramic Science Llc | BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with chronic kidney disease and type 2 diabetes | No dispute reported | 06/30/2026 | 1225404171 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $10,700.00 | 02/14/2025 | Non-covered Recipient Entity Panoramic Health | A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease | No dispute reported | 06/30/2026 | 1220734127 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $360.00 | 02/07/2025 | Non-covered Recipient Entity Panoramic Science Llc | BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with chronic kidney disease and type 2 diabetes | No dispute reported | 06/30/2026 | 1225403191 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $15,139.69 | 02/05/2025 | Non-covered Recipient Entity PANORAMIC HEALTH | A Randomised,Double Blind,Placebo Controlled,Parallel Group Study to Assess the Efficacy and Safety of Baxdrostat in Participants with Uncontrolled Hypertension on Two or More Medications including Participants with Resistant Hypertension | No dispute reported | 06/30/2026 | 1185545441 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $11,393.10 | 02/03/2025 | Non-covered Recipient Entity Clinical Renal Associates, Ltd | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215519814 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $780.00 | 01/29/2025 | Non-covered Recipient Entity Panoramic Science Llc | BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in partic | No dispute reported | 06/30/2026 | 1225411804 |
| Principal investigator 1 | Amgen Inc. | $1,009,060.13 | 01/27/2025 | Non-covered Recipient Entity SOUTHWEST KIDNEY INSTITUTE | A Randomized, Double-blind, Placebo-controlled Phase 4 Clinical Trial to Evaluate the Long-term Safety and Efficacy of Avacopan in Participants With Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis | No dispute reported | 06/30/2026 | 1246648511 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $600.00 | 01/24/2025 | Non-covered Recipient Entity Panoramic Science Llc | BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in partic | No dispute reported | 06/30/2026 | 1225411776 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $3,500.00 | 01/13/2025 | Non-covered Recipient Entity Panoramic Science Llc | BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in partic | No dispute reported | 06/30/2026 | 1225411764 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,970.00 | 01/08/2025 | Non-covered Recipient Entity Clinical Renal Associates, Ltd | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215519778 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $237,235.92 | 01/03/2025 | Non-covered Recipient Entity PANORAMIC HEALTH | a phase 3,randomised,double blind,active controlled study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on chronic kidney disease ckd progression in participants with ckd and high blood pressure | No dispute reported | 06/30/2026 | 1185545435 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $53,169.82 | 01/03/2025 | Non-covered Recipient Entity PANORAMIC HEALTH | A Randomised Double-Blind Placebo-Controlled Parallel Group Study to Assess the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants with Resistant Hypertension | No dispute reported | 06/30/2026 | 1185545437 |